Palliation of bone cancer pain by antagonists of platelet-activating factor receptors

Katsuya Morita, Seiji Shiraishi, Naoyo Motoyama, Tomoya Kitayama, Takashi Kanematsu, Yasuhito Uezono, Toshihiro Dohi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bone cancer pain is the most severe among cancer pain and is often resistant to current analgesics. Thus, the development of novel analgesics effective at treating bone cancer pain are desired. Platelet-activating factor (PAF) receptor antagonists were recently demonstrated to have effective pain relieving effects on neuropathic pain in several animal models. The present study examined the pain relieving effect of PAF receptor antagonists on bone cancer pain using the femur bone cancer (FBC) model in mice. Animals were injected with osteolytic NCTC2472 cells into the tibia, and subsequently the effects of PAF receptor antagonists on pain behaviors were evaluated. Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. The pain relieving effects of these antagonists were achieved with low doses and were long lasting. Blockade of spinal PAF receptors by intrathecal injection of TCV-309 and WEB 2086 or knockdown of the expression of spinal PAF receptor protein by intrathecal transfer of PAF receptor siRNA also produced a pain relieving effect. The amount of an inducible PAF synthesis enzyme, lysophosphatidylcholine acyltransferase 2 (LPCAT2) protein significantly increased in the spinal cord after transplantation of NCTC 2472 tumor cells into mouse tibia. The combination of morphine with PAF receptor antagonists develops marked enhancement of the analgesic effect against bone cancer pain without affecting morphine-induced constipation. Repeated administration of TCV-309 suppressed the appearance of pain behaviors and prolonged survival of FBC mice. The present results suggest that PAF receptor antagonists in combination with, or without, opioids may represent a new strategy for the treatment of persistent bone cancer pain and improve the quality of life of patients. Copyright:

Original languageEnglish
Article numbere91746
JournalPloS one
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 17 2014
Externally publishedYes

Fingerprint

Bone Neoplasms
platelet-activating factor
pain
antagonists
Bone
bones
receptors
neoplasms
analgesic effect
Pain
WEB 2086
Femur
Analgesics
femur
Tibia
Morphine
morphine
animal models
analgesics
1-Acylglycerophosphocholine O-Acyltransferase

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Morita, K., Shiraishi, S., Motoyama, N., Kitayama, T., Kanematsu, T., Uezono, Y., & Dohi, T. (2014). Palliation of bone cancer pain by antagonists of platelet-activating factor receptors. PloS one, 9(3), [e91746]. https://doi.org/10.1371/journal.pone.0091746

Palliation of bone cancer pain by antagonists of platelet-activating factor receptors. / Morita, Katsuya; Shiraishi, Seiji; Motoyama, Naoyo; Kitayama, Tomoya; Kanematsu, Takashi; Uezono, Yasuhito; Dohi, Toshihiro.

In: PloS one, Vol. 9, No. 3, e91746, 17.03.2014.

Research output: Contribution to journalArticle

Morita, K, Shiraishi, S, Motoyama, N, Kitayama, T, Kanematsu, T, Uezono, Y & Dohi, T 2014, 'Palliation of bone cancer pain by antagonists of platelet-activating factor receptors', PloS one, vol. 9, no. 3, e91746. https://doi.org/10.1371/journal.pone.0091746
Morita, Katsuya ; Shiraishi, Seiji ; Motoyama, Naoyo ; Kitayama, Tomoya ; Kanematsu, Takashi ; Uezono, Yasuhito ; Dohi, Toshihiro. / Palliation of bone cancer pain by antagonists of platelet-activating factor receptors. In: PloS one. 2014 ; Vol. 9, No. 3.
@article{19601dcd70e44efeb61f690a1c120fa5,
title = "Palliation of bone cancer pain by antagonists of platelet-activating factor receptors",
abstract = "Bone cancer pain is the most severe among cancer pain and is often resistant to current analgesics. Thus, the development of novel analgesics effective at treating bone cancer pain are desired. Platelet-activating factor (PAF) receptor antagonists were recently demonstrated to have effective pain relieving effects on neuropathic pain in several animal models. The present study examined the pain relieving effect of PAF receptor antagonists on bone cancer pain using the femur bone cancer (FBC) model in mice. Animals were injected with osteolytic NCTC2472 cells into the tibia, and subsequently the effects of PAF receptor antagonists on pain behaviors were evaluated. Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. The pain relieving effects of these antagonists were achieved with low doses and were long lasting. Blockade of spinal PAF receptors by intrathecal injection of TCV-309 and WEB 2086 or knockdown of the expression of spinal PAF receptor protein by intrathecal transfer of PAF receptor siRNA also produced a pain relieving effect. The amount of an inducible PAF synthesis enzyme, lysophosphatidylcholine acyltransferase 2 (LPCAT2) protein significantly increased in the spinal cord after transplantation of NCTC 2472 tumor cells into mouse tibia. The combination of morphine with PAF receptor antagonists develops marked enhancement of the analgesic effect against bone cancer pain without affecting morphine-induced constipation. Repeated administration of TCV-309 suppressed the appearance of pain behaviors and prolonged survival of FBC mice. The present results suggest that PAF receptor antagonists in combination with, or without, opioids may represent a new strategy for the treatment of persistent bone cancer pain and improve the quality of life of patients. Copyright:",
author = "Katsuya Morita and Seiji Shiraishi and Naoyo Motoyama and Tomoya Kitayama and Takashi Kanematsu and Yasuhito Uezono and Toshihiro Dohi",
year = "2014",
month = "3",
day = "17",
doi = "10.1371/journal.pone.0091746",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Palliation of bone cancer pain by antagonists of platelet-activating factor receptors

AU - Morita, Katsuya

AU - Shiraishi, Seiji

AU - Motoyama, Naoyo

AU - Kitayama, Tomoya

AU - Kanematsu, Takashi

AU - Uezono, Yasuhito

AU - Dohi, Toshihiro

PY - 2014/3/17

Y1 - 2014/3/17

N2 - Bone cancer pain is the most severe among cancer pain and is often resistant to current analgesics. Thus, the development of novel analgesics effective at treating bone cancer pain are desired. Platelet-activating factor (PAF) receptor antagonists were recently demonstrated to have effective pain relieving effects on neuropathic pain in several animal models. The present study examined the pain relieving effect of PAF receptor antagonists on bone cancer pain using the femur bone cancer (FBC) model in mice. Animals were injected with osteolytic NCTC2472 cells into the tibia, and subsequently the effects of PAF receptor antagonists on pain behaviors were evaluated. Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. The pain relieving effects of these antagonists were achieved with low doses and were long lasting. Blockade of spinal PAF receptors by intrathecal injection of TCV-309 and WEB 2086 or knockdown of the expression of spinal PAF receptor protein by intrathecal transfer of PAF receptor siRNA also produced a pain relieving effect. The amount of an inducible PAF synthesis enzyme, lysophosphatidylcholine acyltransferase 2 (LPCAT2) protein significantly increased in the spinal cord after transplantation of NCTC 2472 tumor cells into mouse tibia. The combination of morphine with PAF receptor antagonists develops marked enhancement of the analgesic effect against bone cancer pain without affecting morphine-induced constipation. Repeated administration of TCV-309 suppressed the appearance of pain behaviors and prolonged survival of FBC mice. The present results suggest that PAF receptor antagonists in combination with, or without, opioids may represent a new strategy for the treatment of persistent bone cancer pain and improve the quality of life of patients. Copyright:

AB - Bone cancer pain is the most severe among cancer pain and is often resistant to current analgesics. Thus, the development of novel analgesics effective at treating bone cancer pain are desired. Platelet-activating factor (PAF) receptor antagonists were recently demonstrated to have effective pain relieving effects on neuropathic pain in several animal models. The present study examined the pain relieving effect of PAF receptor antagonists on bone cancer pain using the femur bone cancer (FBC) model in mice. Animals were injected with osteolytic NCTC2472 cells into the tibia, and subsequently the effects of PAF receptor antagonists on pain behaviors were evaluated. Chemical structurally different type of antagonists, TCV-309, BN 50739 and WEB 2086 ameliorated the allodynia and improved pain behaviors such as guarding behavior and limb-use abnormalities in FBC model mice. The pain relieving effects of these antagonists were achieved with low doses and were long lasting. Blockade of spinal PAF receptors by intrathecal injection of TCV-309 and WEB 2086 or knockdown of the expression of spinal PAF receptor protein by intrathecal transfer of PAF receptor siRNA also produced a pain relieving effect. The amount of an inducible PAF synthesis enzyme, lysophosphatidylcholine acyltransferase 2 (LPCAT2) protein significantly increased in the spinal cord after transplantation of NCTC 2472 tumor cells into mouse tibia. The combination of morphine with PAF receptor antagonists develops marked enhancement of the analgesic effect against bone cancer pain without affecting morphine-induced constipation. Repeated administration of TCV-309 suppressed the appearance of pain behaviors and prolonged survival of FBC mice. The present results suggest that PAF receptor antagonists in combination with, or without, opioids may represent a new strategy for the treatment of persistent bone cancer pain and improve the quality of life of patients. Copyright:

UR - http://www.scopus.com/inward/record.url?scp=84898604655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898604655&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0091746

DO - 10.1371/journal.pone.0091746

M3 - Article

C2 - 24637403

AN - SCOPUS:84898604655

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e91746

ER -